Business Context and Reporting Period
Spectral AI, Inc. filed a Form 8-K reporting the execution of a material contract with the Biomedical Advanced Research and Development Authority (BARDA) on September 27, 2023. The report was signed and dated September 28, 2023. Spectral AI develops the DeepView® System, an AI-driven burn wound imaging technology intended for emergency departments, trauma centers, burn centers, routine burn care, and burn mass-casualty incidents.
Key Financial and Operating Metrics
- The BARDA contract could provide payments to Spectral AI of up to approximately $149 million.
- The contract includes an initial base period and option periods that BARDA may exercise.
- Payments and continued performance are subject to specified milestones and deliverables.
- Including previously awarded BARDA contracts, total BARDA support could reach nearly $251 million.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or current-period financial statement metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial results. The material development is the new BARDA contract and the resulting increase in potential cumulative BARDA support to nearly $251 million.
Guidance, Outlook, Risks, and Unusual Items
- The contract supports the advanced development of the DeepView System and its potential use as a medical countermeasure.
- The disclosed amount is a potential maximum, not a guaranteed payment or recognized revenue amount.
- Option periods are discretionary for BARDA and depend on Spectral AI achieving specified milestones and deliverables.
- The government has customary rights under the contract, including the right to terminate for convenience at any time.
- The filing does not provide broader revenue guidance, commercialization timing, profitability expectations, or a specific schedule for contract payments.
- The complete contract was to be filed as an exhibit to Spectral AI’s Form 10-Q for the period ending September 30, 2023.
Important Facts for Investors to Verify
- Review the complete BARDA contract for milestone requirements, option-period terms, payment timing, reimbursement provisions, and termination rights.
- Verify how and when contract awards are recognized as revenue under applicable accounting guidance.
- Assess the likelihood and timing of BARDA exercising option periods and the associated funding.
- Review subsequent filings for contract performance, recognized revenue, remaining funding, cash receipts, and any amendments or termination notices.
- Consider regulatory, clinical, commercialization, manufacturing, and government procurement risks affecting the DeepView System.